Venture cash piling on to beat 1Q total
This article was originally published in Scrip
Executive Summary
Biotechnology companies announced another $242.5m in venture capital funding during the week ended Friday, 25 April, keeping the second quarter on track to beat the $1.1bn that biotech firms raised during the first quarter.
You may also be interested in...
Finance Watch: Two New VC Funds Raise $500m; One New US IPO; And Galena's 'Strategic Review'
Pivotal and Biomatics launch new VC funds totaling $300m and $200m, respectively; Spero raises a $51.7m Series C round; BeyondSpring is March's only US IPO, so far; Aurinia and TG Therapeutics capitalize on positive data with secondary offerings; and Galena hires a "strategic review" advisor.
CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
ARCH Cites Stability Of Long-Term Investors In Raising $3bn Fund
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.